Retinoblastoma screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Sahar}} {{Simrat}} | {{CMG}}; {{AE}} {{Sahar}} {{Simrat}} | ||
==Overview== | ==Overview== | ||
Early [[diagnosis]] of | Early [[diagnosis]] of retinoblastoma is necessary to obtain the best outcomes for preservation of the [[vision]] and the eye. In 2018, a group of experts in clinical retinoblastoma care and [[ophthalmic]] | ||
[[pathology]] and [[genetics]] | [[pathology]] and [[genetics]] suggested a risk-stratified schedule for [[ophthalmic]] [[screening]] [[Examination|examinations]]. Estimated risk of retinoblastoma development is calculated according to the relativity of individuals to the family member with retinoblastoma. | ||
==Screening== | ==Screening== | ||
* In 2018, a group of experts in clinical retinoblastoma care and [[ophthalmic]] [[pathology]] and [[genetics]] suggested a risk-stratified schedule for [[ophthalmic]] [[Screening (medicine)|screening]] [[Examination|examinations]].<ref name="SkaletGombos2018">{{cite journal|last1=Skalet|first1=Alison H.|last2=Gombos|first2=Dan S.|last3=Gallie|first3=Brenda L.|last4=Kim|first4=Jonathan W.|last5=Shields|first5=Carol L.|last6=Marr|first6=Brian P.|last7=Plon|first7=Sharon E.|last8=Chévez-Barrios|first8=Patricia|title=Screening Children at Risk for Retinoblastoma|journal=Ophthalmology|volume=125|issue=3|year=2018|pages=453–458|issn=01616420|doi=10.1016/j.ophtha.2017.09.001}}</ref> | |||
pathology and genetics | * This panel of experts recommended that all [[Child|children]] with an elevated risk of retinoblastoma (above the population risk) should be [[Screening (medicine)|screened]] via regular [[Fundoscopy|fundoscopic examination]]. | ||
*To schedule a [[screening]] plan, the risk of [[tumor]] development must be determined using the [[infant]] relationship to the family member with retinoblastoma. | |||
*The table below is an estimate of [[Patient|patients]] risk for the development of retinoblastoma depending on the relativity of [[patient]] to the affected relatives. | |||
*To schedule | |||
*The table below is an estimate of patients risk for the development of | |||
{| border="3" | {| border="3" | ||
|+ Risk of carrying [[mutated]] [[gene]] in the relatives of a patient with | |+ Risk of carrying [[mutated]] [[gene]] in the relatives of a patient with retinoblastoma (Patient)(%) | ||
! Relative of patient !! Bilateral involvement (100%) !! Unilateral involvement (15%) | ! Relative of patient !! Bilateral involvement (100%) !! Unilateral involvement (15%) | ||
|- | |- | ||
| Line 43: | Line 41: | ||
|- | |- | ||
|} | |} | ||
Next step in assessing the risk of these children is to estimate the approximate relative risk of | Next step in assessing the risk of these children is to estimate the approximate relative risk of retinoblastoma development according to the percentage mentioned in the aforementioned table. | ||
*Relatives are categorized into three categories: | *Relatives are categorized into three categories: | ||
**High risk: those with risk percentage > 7.5% | **High risk: those with risk percentage > 7.5% | ||
**Intermediate risk: those with risk percentage between and 1% and 7.5% (including 7.5%). | **Intermediate risk: those with risk percentage between and 1% and 7.5% (including 7.5%). | ||
**Low risk: those with risk percentage < 1%. | **Low risk: those with risk percentage < 1%. | ||
*American Association of [[Ophthalmic]] [[Oncologists]] and [[Pathologists]] (AAOOP) guideline recommends scheduled [[eye examination]] for the [[screening]] of children at higher risk of | *American Association of [[Ophthalmic]] [[Oncologists]] and [[Pathologists]] (AAOOP) guideline recommends scheduled [[eye examination]] for the [[screening]] of children at higher risk of retinoblastoma. <ref name="SkaletGombos2018">{{cite journal|last1=Skalet|first1=Alison H.|last2=Gombos|first2=Dan S.|last3=Gallie|first3=Brenda L.|last4=Kim|first4=Jonathan W.|last5=Shields|first5=Carol L.|last6=Marr|first6=Brian P.|last7=Plon|first7=Sharon E.|last8=Chévez-Barrios|first8=Patricia|title=Screening Children at Risk for Retinoblastoma|journal=Ophthalmology|volume=125|issue=3|year=2018|pages=453–458|issn=01616420|doi=10.1016/j.ophtha.2017.09.001}}</ref> | ||
*This society recommends [[screening]] from birth up to 7 years of age. | *This society recommends [[screening]] from birth up to 7 years of age. | ||
*No further [[Eye examination|examination]] is required after this age except for those who are known carriers of the [[RB1]] [[gene]] [[mutation]]. | *No further [[Eye examination|examination]] is required after this age except for those who are known carriers of the [[RB1]] [[gene]] [[mutation]]. | ||
*For those who carries the [[RB1]] [[gene]] [[mutation]], [[screening]] should be continued indefinitely after the age of 7 years annually or every 2 years. | *For those who carries the [[RB1]] [[gene]] [[mutation]], [[screening]] should be continued indefinitely after the age of 7 years annually or every 2 years. | ||
The following table is the recommended [[eye examination]] schedule for unaffected children of families with | The following table is the recommended [[eye examination]] schedule for unaffected children of families with retinoblastoma depending on their age and risk percentage of tumor development. | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | ||
| valign="top" | | | valign="top" | | ||
| Line 138: | Line 136: | ||
|} | |} | ||
*The schedule presented above is general guideline for at-risk child when no [[Lesion|lesions]] of concern have been noted. Some children may require more frequent [[Eye examination|examinations]]. | *The schedule presented above is general guideline for at-risk child when no [[Lesion|lesions]] of concern have been noted. Some children may require more frequent [[Eye examination|examinations]]. | ||
The AAOOP guideline also suggests a single dilated fundus examination to evaluate for [[asymptomatic]] spontaneously regressed | The AAOOP guideline also suggests a single dilated fundus examination to evaluate for [[asymptomatic]] spontaneously regressed retinoblastoma or retinoma in all first-degree relatives of a patient with retinoblastoma, including older siblings if the [[RB1]] [[genetic analysis]] of the relatives is not done. | ||
===[[Genetic testing]] for child with | ===[[Genetic testing]] for child with Retinoblastoma=== | ||
{{familytree/start}} | {{familytree/start}} | ||
{{familytree | | | | | | | | | | | | | | | A01 | | | | | |A01=[[Genetic testing]] for child with [[Retinoblastoma]]}} | {{familytree | | | | | | | | | | | | | | | A01 | | | | | |A01=[[Genetic testing]] for child with [[Retinoblastoma]]}} | ||
Revision as of 16:45, 11 June 2019
|
Retinoblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Retinoblastoma screening On the Web |
|
American Roentgen Ray Society Images of Retinoblastoma screening |
|
Risk calculators and risk factors for Retinoblastoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Simrat Sarai, M.D. [3]
Overview
Early diagnosis of retinoblastoma is necessary to obtain the best outcomes for preservation of the vision and the eye. In 2018, a group of experts in clinical retinoblastoma care and ophthalmic pathology and genetics suggested a risk-stratified schedule for ophthalmic screening examinations. Estimated risk of retinoblastoma development is calculated according to the relativity of individuals to the family member with retinoblastoma.
Screening
- In 2018, a group of experts in clinical retinoblastoma care and ophthalmic pathology and genetics suggested a risk-stratified schedule for ophthalmic screening examinations.[1]
- This panel of experts recommended that all children with an elevated risk of retinoblastoma (above the population risk) should be screened via regular fundoscopic examination.
- To schedule a screening plan, the risk of tumor development must be determined using the infant relationship to the family member with retinoblastoma.
- The table below is an estimate of patients risk for the development of retinoblastoma depending on the relativity of patient to the affected relatives.
| Relative of patient | Bilateral involvement (100%) | Unilateral involvement (15%) |
|---|---|---|
| Offspring (infant) | 50 | 7.5 |
| Parent | 5 | 0.8 |
| Sibling | 2.5 | 0.4 |
| Niece/nephew | 1.3 | 0.2 |
| Aunt/uncle | 0.1 | 0.007 |
| First cousin | 0.05 | 0.007 |
| The above table adopted from Ophthalmology journal [1] |
|---|
Next step in assessing the risk of these children is to estimate the approximate relative risk of retinoblastoma development according to the percentage mentioned in the aforementioned table.
- Relatives are categorized into three categories:
- High risk: those with risk percentage > 7.5%
- Intermediate risk: those with risk percentage between and 1% and 7.5% (including 7.5%).
- Low risk: those with risk percentage < 1%.
- American Association of Ophthalmic Oncologists and Pathologists (AAOOP) guideline recommends scheduled eye examination for the screening of children at higher risk of retinoblastoma. [1]
- This society recommends screening from birth up to 7 years of age.
- No further examination is required after this age except for those who are known carriers of the RB1 gene mutation.
- For those who carries the RB1 gene mutation, screening should be continued indefinitely after the age of 7 years annually or every 2 years.
The following table is the recommended eye examination schedule for unaffected children of families with retinoblastoma depending on their age and risk percentage of tumor development.
| Risk category or Age | High risk | Intermediate risk | Low risk |
|---|---|---|---|
|
Birth to 8 weeks |
|
|
|
|
>8-12 weeks |
|
|
|
|
>3 to 12 months |
|
|
|
|
>12 to 24 months |
|
|
|
|
>24 to 36 months |
|
|
|
|
>36 to 48 months |
|
|
|
|
>48 to 60 months |
|
|
|
|
5 to 7 years |
|
|
|
| The above table is the recommended management guideline for childhood screening of families with affected individuals and adopted from Ophthalmology journal[1] |
|---|
- The schedule presented above is general guideline for at-risk child when no lesions of concern have been noted. Some children may require more frequent examinations.
The AAOOP guideline also suggests a single dilated fundus examination to evaluate for asymptomatic spontaneously regressed retinoblastoma or retinoma in all first-degree relatives of a patient with retinoblastoma, including older siblings if the RB1 genetic analysis of the relatives is not done.
Genetic testing for child with Retinoblastoma
| Genetic testing for child with Retinoblastoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Not available | Blood:RB1 mutation(+) (germline mutation) | Blood:RB1 mutation(-) Tumor:RB1 mutation(+) | Blood:RB1 mutation(-) tumor:RB1 mutation(-) | Blood:RB1 mutation(-) Tumor:not available | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Ophthalmic screnning for all the relatives with greater than population risk | Assessment of relatives for familial retinoblastoma | Ophthalmic screening and genetic analysis not required for 1-degree relatives | No need for genetic analysis of 1-degree relatives | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Relatives with RB1 mutation | Relatives w/o RB1 mutation | Ophthlamic screening for future offspring unless negative for parent's mutation | Future offspring of affected child require ophthalmic screening | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ophthalmic screening for children as high risk | Ophthalmic screening not required | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The above table is the recommended genetic analysis guidline for families with affected individuals and adopted from Ophthalmology journal[1] |
|---|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Skalet, Alison H.; Gombos, Dan S.; Gallie, Brenda L.; Kim, Jonathan W.; Shields, Carol L.; Marr, Brian P.; Plon, Sharon E.; Chévez-Barrios, Patricia (2018). "Screening Children at Risk for Retinoblastoma". Ophthalmology. 125 (3): 453–458. doi:10.1016/j.ophtha.2017.09.001. ISSN 0161-6420.